As per the analyst, the transformation consists of inventory and debt reduction, and divestitures, together with an agile organizational structure ... Eastman Chemical Company (NYSE:EMN) operates ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

A new study led by researchers at the Earth-Life Science Institute (ELSI) at Institute of Science Tokyo has uncovered a surprising role for calcium in shaping life's earliest molecular structures.

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain ...

Dupilumab treatment of atopic dermatitis (AD) resulted in long-term skin improvements linked to changes in skin’s the molecular composition, according to study findings published in the Journal of ...

Chovatiya also discussed patient outcomes from ADAPT trial, which looked at patients who had previously been treated with dupilumab and the ADmirable trial, which looked at AD in people of color.

In September 2024, Sanofi acknowledged that the first study of its Phase III LIBERTY-CPUO-CHIC program (NCT05263206) evaluating Dupixent ® (dupilumab) in adults with uncontrolled and severe CPUO ...